Moderna, Inc. (MRNA)

Last Price: 69.26 (2020-09-21)

Company Description

Moderna Inc. is a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines for patients. The company's product pipeline which is in clinical stage consists of mRNA-1647 for Cytomegalovirus Infectious Disease, mRNA-4157 for Solid tumors, mRNA-2416 for lymphoma and mRNA- 2752 for Relapsed/Refractory solid tumors malignancies. Moderna Inc. is based in Cambridge, United States.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $60.21M
Net Income (Most Recent Fiscal Year) $-514.02M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) 260.48
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 8.80
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -460.67%
Net Margin (Trailing 12 Months) -461.42%
Return on Equity (Trailing 12 Months) -27.85%
Return on Assets (Trailing 12 Months) -22.37%
Current Ratio (Most Recent Fiscal Quarter) 17.30
Quick Ratio (Most Recent Fiscal Quarter) 17.30
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $3.49
Earnings per Share (Most Recent Fiscal Quarter) $-0.31
Earnings per Share (Most Recent Fiscal Year) $-1.55
Diluted Earnings per Share (Trailing 12 Months) $-1.40
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 394.59M
Free Float 279.37M
Market Capitalization $27.57B
Average Volume (Last 20 Days) 11.02M
Beta (Past 60 Months) 0.47
Percentage Held By Insiders (Latest Annual Proxy Report) 29.20%
Percentage Held By Institutions (Latest 13F Reports) 55.04%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%